Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2016

View Archived Issues

Novartis reviews key milestones of fourth quarter 2015

Optogenetic modulation of response by controlling Ca2+ flow into cells: NIR-activated immunotherapy

Research Council of Norway awards funding to Bionor and Nordic Nanovector

Corvus initiates phase I/Ib study of CPI-444 in advanced cancer

Companies investigate approaches to tackle Zika virus

Shionogi updates progress of third quarter of fiscal 2015

Targovax submits a study protocol for ONCOS-102 trial to the regulatory authorities in Spain

AbbVie updates pipeline progress of fourth quarter 2015

The Medicines Company completes divestiture of hemostasis portfolio to Mallinckrodt

Recurrent genetic alterations identified in low-grade neuroepithelial tumors

Ligand licenses use of OmniAb platform to Tizona Therapeutics

Endomorphin analogues show potent analgesia with low side-effect profile

Repurposing RXR agonist HX-630: Possible new treatment for Cushing's disease?

Abbott to acquire Alere

Ono Pharmaceutical recaps highlights of third quarter of fiscal 2015

Neurocrine initiates phase II study of valbenazine in pediatric patients with Tourette syndrome

LEO Pharma and arGEN-X select cell line for manufacture of antibody against skin inflammation

Trimesta shows no benefit in relapsing-remitting MS in women

Versartis reports results from extension study of somavaratan in children with GHD

FDA issues CRL regarding Telesta Therapeutics' MCNA

Tagrisso approved in E.U. for EGFR-mutant NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...